Middle East and Africa Next-generation Sequencing (NGS) Market Report

Middle East and Africa Next-generation Sequencing (NGS) Market Size

The Middle East and Africa next-generation sequencing (NGS) market size was valued at USD 0.32 billion in 2025 and is anticipated to reach USD 0.38 billion in 2026 from USD 1.41 billion by 2034, growing at a CAGR of 17.80% during the forecast period from 2026 to 2034.

Next-Generation Sequencing (NGS) is a high-throughput genomic technology enabling rapid and parallel sequencing of DNA and RNA across clinical, research, and public health applications. Unlike traditional Sanger sequencing, NGS allows for the simultaneous analysis of millions of genetic fragments by facilitating advancements in precision medicine, infectious disease surveillance, and agricultural genomics. The region’s increasing focus on genetic epidemiology is supported by the prevalence of hereditary disorders. Like, according to the World Health Organization, consanguineous marriages affect over 25% of unions in several Gulf countries, contributing to a higher burden of monogenic diseases such as thalassemia and spinal muscular atrophy.

MARKET DRIVERS

Expansion of National Genomic Medicine Initiatives

Launch of state-backed genomics programs by several countries in the region is propelling the growth of the Middle East & Africa Next-Generation Sequencing (NGS) market. In Saudi Arabia, its program aims to sequence a significant quantity of genomes by 2030 to map hereditary disease patterns and support precision diagnostics, with substantial genomes sequenced by the end of 2023, as per the research. Similarly, the UAE launched the Emirati Genome Program, targeting citizens to identify genetic predispositions to diabetes, cardiovascular diseases, and rare conditions. According to the Dubai Health Authority, the program has already enabled early diagnosis in numerous cases of previously undiagnosed rare diseases. These initiatives are supported by substantial government funding and public-private partnerships by creating a structured demand for sequencing infrastructure, bioinformatics platforms, and trained personnel across clinical laboratories.

Rising Burden of Infectious and Genetic Diseases

The high prevalence of both communicable and inherited disorders in the region has created a compelling medical need for advanced diagnostic tools, which is accelerating the growth of Middle East & Africa Next-Generation Sequencing (NGS) market. Tuberculosis is a public health challenge, with significant new cases reported annually in Africa, many involving drug-resistant strains. NGS enables rapid identification of resistance mutations by improving treatment outcomes. In South Africa, it used whole-genome sequencing to track the emergence of SARS-CoV-2 variants by sequencing several samples during the pandemic.

MARKET RESTRAINTS

Limited Genomic Infrastructure and Laboratory Accreditation

The scarcity of accredited sequencing facilities and standardized laboratory protocols is restraining the growth of the Middle East & Africa Next-Generation Sequencing (NGS) market. Fewer laboratories across sub-Saharan Africa are equipped with NGS platforms and only few are accredited under ISO 15189 standards. In countries like Kenya and Nigeria, most genomic testing is outsourced to facilities in Europe or the United States which delayes results and increases costs. As per study, a portion of private hospitals in the GCC still rely on off-site sequencing for clinical diagnostics due to in-house capability gaps. Furthermore, inconsistent regulatory oversight across countries hampers data sharing and quality assurance. This fragmented infrastructure limits equitable access to genomic medicine and discourages investment in localized sequencing capacity which constrains the scalability of NGS applications in both research and clinical settings.

Shortage of Skilled Bioinformaticians and Genomic Data Scientists

The lack of trained professionals capable of analyzing and interpreting complex genomic datasets is also restraining the growth of Middle East & Africa Next-Generation Sequencing (NGS) market. Africa produces a smaller share of global genomic research despite hosting immense genetic diversity and this is largely due to human resource gaps. As of 2023, there was a small number of certified bioinformaticians in the entire African continent, as per the research. In the Middle East, while sequencing hardware is increasingly available, institutions such as King Faisal Specialist Hospital in Riyadh and Cairo University Hospitals face challenges in retaining data scientists due to limited academic training programs.

MARKET OPPORTUNITIES

Growth of Public-Private Partnerships in Genomic Research

The public-private collaborations is a key factor prompting new opportunities for the growth of Middle East & Africa Next-Generation Sequencing (NGS) market. In addition, the Qatar Genome Programme partnered with Illumina to establish a national sequencing center capable of processing significant genomes annually by focusing on Arab-specific disease variants. As per the study, such partnerships have increased research funding over the past years. These alliances not only enhance technological access but also facilitate knowledge transfer, regulatory alignment, and workforce development, laying the foundation for sustainable genomic medicine ecosystems.

Integration of NGS into Precision Oncology Programs

Cancer care modernization is another opportunity for the expansion of the Middle East & Africa Next-Generation Sequencing (NGS) market. As per the International Agency for Research on Cancer (IARC), breast, liver, and cervical cancers are among the most prevalent in Africa, with late diagnosis contributing to high mortality. In response, countries like Saudi Arabia and South Africa are incorporating NGS into national oncology strategies to enable tumor profiling and targeted therapy selection. The King Hussein Cancer Center in Jordan has implemented routine NGS testing for non-small cell lung cancer, identifying actionable mutations in a portion of patients, as per the study. In Egypt, the National Cancer Institute in Cairo launched a liquid biopsy pilot using NGS to monitor treatment response in advanced cases. These clinical applications are improving survival outcomes and driving demand for scalable, cost-effective sequencing platforms tailored to regional cancer epidemiology.

MARKET CHALLENGES

Data Privacy and Ethical Governance Gaps in Genomic Research

The absence of comprehensive legal frameworks governing genomic data ownership, consent, and cross-border sharing is challenging the growth of the Middle East & Africa Next-Generation Sequencing (NGS) market. As per the study, only a few countries may have separate, specific genetic data protection laws, many African countries have passed broader data protection legislation that classifies genetic and health information as "sensitive data" and subjects it to stricter safeguards. Many countries lack the resources and institutional capacity needed to enforce their data protection laws effectively. In addition, a data audit revealed that the number of genomic research projects lacked standardized informed consent protocols, particularly in rural trial sites. Besides, concerns over genetic stigmatization, especially for hereditary conditions in consanguineous communities, have led to public hesitancy.

High Cost and Import Dependency of NGS Platforms

The financial and logistical barriers to acquiring and maintaining NGS infrastructure is challenging the growth of the Middle East & Africa Next-Generation Sequencing (NGS) market. Most next-generation sequencers, reagents, and software are imported from the United States, Europe, or China, exposing laboratories to currency fluctuations and supply chain delays. In Nigeria, import duties and customs clearance delays can extend equipment delivery months, as per the research. Besides, recurring costs for bioinformatics software licenses and cloud storage limit long-term sustainability. This dependency on foreign technology impedes self-reliance and restricts the scalability of NGS programs in low-resource settings where funding is already constrained.

SEGMENTAL ANALYSIS

By Product Insights

The services segment dominated the Middle East & Africa Next-Generation Sequencing (NGS) Market by capturing 62.6% share in 2024. The growth of segment is driven by the region’s reliance on outsourced sequencing and data analysis due to limited in-house capabilities. In countries such as Nigeria, Kenya, and Egypt, most research institutions and hospitals lack the infrastructure to perform end-to-end NGS workflows, necessitating partnerships with international service providers. According to the study, a notable share of genomic studies conducted in sub-Saharan Africa utilized external sequencing services based in Europe or North America.

The software segment is projected to register the highest CAGR of 15.3% from 2025 to 2033 due to the growing need for localized, cloud-based bioinformatics platforms capable of handling Arab- and African-specific genomic data. As sequencing volumes rise through national programs in Saudi Arabia and South Africa, institutions are investing in software solutions for variant calling, data visualization, and clinical reporting. In addition, a few regional authorities in MEA require the use of certified genomic interpretation software in all licensed diagnostic labs, accelerating adoption. Besides, open-source tools like Galaxy Africa and CLC Genomics Workbench are being customized for regional research needs.

By Technology Insights

The targeted re-sequencing segment led the Middle East & Africa Next-Generation Sequencing (NGS) Market by accounting for a 38.5% in 2024. The growth of the targeted re-sequencing segment is attributed to its cost-effectiveness, high depth of coverage, and clinical applicability in diagnosing known genetic disorders. In regions with high prevalence of hereditary conditions, such as thalassemia in Egypt and sickle cell disease in Kenya, targeted panels enable rapid screening of specific mutations without the expense of whole-genome analysis. According to the research, many prenatal tests for hemoglobinopathies were conducted using targeted NGS to prevent thousands of high-risk births. The technology’s compatibility with low-input samples and shorter turnaround times makes it ideal for clinical diagnostics, which strengthens its dominance in both public health and hospital-based genomics.

The whole genome sequencing (WGS) segment is projected to grow at a fastest CAGR of 16.7% during the forecast period. The growth of the WGS segment is driven by national genome programs in the Gulf and increasing research into population-specific disease variants. Saudi Arabia’s goal of sequencing substantial genomes by 2030 has driven large-scale WGS adoption, with significant whole genomes sequenced, as per the study. In South Africa, it is piloting WGS for tuberculosis strain tracking, improving outbreak response and drug resistance detection. Apart from these, WGS is becoming more affordable.

By Application Insights

The diagnostics segment accounted in holding 45.3% of the Middle East & Africa Next-Generation Sequencing (NGS) Market share in 2024 with the urgent need for early and accurate detection of genetic and infectious diseases. The South African National Institute for Communicable Diseases (NICD) employs NGS for real-time surveillance of antimicrobial resistance and viral variants.

The personalized medicine segment is predicted to witness the highest CAGR of 17.1% from 2024 to 2033. The growth of the personalized medicine segment is driven by national initiatives to integrate genomic data into treatment planning, particularly in oncology and pharmacogenomics. In Saudi Arabia, the Program at King Abdullah International Medical Research Center uses NGS to guide cancer therapy, identifying targetable mutations in some of non-small cell lung cancer patients, as per the study. Apart from these, private hospitals in South Africa and Egypt are offering NGS-based treatment plans for breast and colorectal cancers.

REGIONAL ANALYSIS

Saudi Arabia was the top performer in the Middle East & Africa Next-Generation Sequencing (NGS) Market and accounted for 24.5% share in 2024 with its national genomic ambitions, particularly the Saudi Human Genome Program, which has sequenced several genomes to map hereditary diseases and support precision medicine. The government has allocated funds to genomics research under Vision 2030, establishing sequencing centers. According to the study, hospitals have access to NGS-based diagnostics for rare diseases and cancer. The country also hosts the Middle East’s largest bioinformatics hub which reduces reliance on external data analysis.

South Africa Next-Generation Sequencing (NGS) Market was ranked second in holding a significant share due to its strong position built on its advanced scientific infrastructure and place in African genomics through the H3Africa Initiative. The National Health Laboratory Service operates one of the continent’s most sophisticated NGS facilities, conducting pathogen surveillance and population genomics. In addition, South Africa sequenced number of SARS-CoV-2 and TB genomes by contributing data to global health databases, as per the research. The University of Cape Town and Stellenbosch University host bioinformatics training programs, addressing human resource gaps. Besides, private diagnostics firms offer clinical NGS panels for oncology and inherited disorders. The

United Arab Emirates is expected to grow with a CAGR of 16.1% from 2025 to 2033. The growth of UAE market is due to its Emirati Genome Program to sequence notable citizens to identify genetic predispositions to chronic diseases. The UAE has also established regulatory frameworks for genomic data privacy and clinical validation by setting regional benchmarks. Apart from these, the country’s integration of NGS into private healthcare networks ensures rapid clinical translation. This fusion of national strategy, regulatory clarity, and technological investment positions the UAE as a model for scalable genomic medicine.

COMPETITIVE LANDSCAPE

The competitive landscape of the Middle East & Africa Next-generation Sequencing (NGS) Market is shaped by a mix of global technology leaders, regional research institutions, and emerging local service providers navigating complex infrastructural and regulatory environments. Multinational corporations such as Illumina, Thermo Fisher Scientific, and BGI Genomics dominate through technological superiority, established supply chains, and strategic government collaborations. However, regional players and academic consortia are gaining influence by focusing on population-specific research and cost-effective diagnostics. Competition is less price-driven and more centered on reliability, technical support, and adaptability to local health priorities.

KEY MARKET PLAYERS

Some of the notable market participants dominating the MEA NGS market profiled in this report are

• Illumina Incorporated
• Thermo Fisher Scientific
• Roche Life Sciences
• Pacific Biosciences
• Life Technologies Corp. (Thermo Fisher Scientific)
• Macrogen Inc.
• Partek Inc.
• Genomatix Software GmbH
• PerkinElmer Inc.
• GATC Biotech AG
• Agilent Technologies Inc.
• Biomatters Ltd.
• CLC Bio (Qiagen)
• BGI (Beijing Genomics Institute)
• Oxford Nanopore Technologies Ltd.
• DNASTAR Inc.
• Knome Inc.
• Qiagen N.V.

Top Players in the Middle East & Africa Next-Generation Sequencing (NGS) Market

Illumina maintains a leading presence in the Middle East & Africa NGS market through its advanced sequencing platforms and strategic collaborations with national genomics initiatives. Illumina has supported the Emirati Genome Program in the UAE and partnered with Qatar Genome to deploy NovaSeq systems for large-scale population sequencing. The company also introduced localized customer support teams in Saudi Arabia and South Africa to streamline instrument maintenance and reagent supply.

Thermo Fisher Scientific plays a pivotal role in advancing NGS adoption across the Middle East and Africa by offering integrated solutions that combine sequencing instrumentation, reagents, and data analysis tools. The company has strengthened its footprint by supplying Ion GeneStudio S5 systems to major research centers, including the South African Medical Research Council and Egypt’s National Research Centre. The company also launched a series of virtual bioinformatics webinars tailored to African researchers by addressing gaps in data interpretation. Furthermore, it established a regional logistics center in Dubai to reduce delivery times for sequencing kits across the continent.

BGI Genomics has significantly expanded its influence in the Middle East and Africa by providing cost-effective sequencing services and establishing local testing infrastructure. In 2023, BGI Genomics signed a Memorandum of Understanding (MoU) with the Armauer Hansen Research Institute (AHRI) in Ethiopia to enhance genomics and precision medicine capabilities. Its strategy of combining affordability, rapid deployment, and public health integration has enabled BGI to establish deep operational roots across diverse healthcare environments in the region.

Top Strategies Used by Key Market Participants

Key players in the Middle East & Africa NGS market are deploying multifaceted strategies to expand their influence and overcome regional barriers. Companies are forming public-private partnerships with governments and research institutions to support national genome programs and disease-specific initiatives. Investment in local training and technical support infrastructure is enhancing workforce capabilities and ensuring sustainable platform utilization. Firms are also tailoring bioinformatics software to interpret population-specific variants by improving clinical relevance. Strategic placement of regional logistics and service centers reduces equipment downtime and reagent delays. Besides, companies are offering flexible financing models and bundled solutions to make NGS more accessible to public hospitals and research labs.

RECENT MARKET DEVELOPMENTS

• In June 2023, Thermo Fisher Scientific deployed the Ion GeneStudio S5 system at the National Research Centre in Cairo, which is supporting Egypt’s national initiative for genetic disease screening and enabling high-throughput sequencing for inherited disorders.
• In January 2024, Illumina expanded its partnership with the Qatar Genome Programme to include data analysis support and bioinformatics training with its role in advancing precision medicine in the Gulf region.

MARKET SEGMENTATION

This research report on the Middle East and Africa NGS Market has been segmented and sub-segmented into the following categories.

By Product

• Software
• Services

By Technology

• Targeted Re-Sequencing
• Whole Genome Sequencing
• De Novo Sequencing
• Exome Sequencing
• RNA-Seq
• ChIP-Seq
• Methyl-Seq

By Application

• Diagnostics
• Drug Discovery
• Biomarker Discovery
• Personalized Medicine
• Agriculture
• Animals Research

By Country

• KSA
• UAE
• Israel
• rest of the GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA